(NASDAQ:VICR), ANDOVER, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) — Vicor Corporation (NASDAQ: VICR) today reported financial results for the fourth quarter and year ended December 31, 2024. These results will be discussed later today at 5:00 p.m. Eastern Time, during management's quarterly investor conference call. The details for the call are below. Revenues for the […]

(NASDAQ:ALTR), TROY, Mich., Feb. 20, 2025 (GLOBE NEWSWIRE) — Altair (Nasdaq: ALTR), a global leader in computational intelligence, today released its financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights Software revenue was $179.4 million compared to $155.9 million for the fourth quarter of 2023, an

(NASDAQ:TERN), FOSTER CITY, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) — Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Robert Azelby, a seasoned biotechnology executive and board director, to the Company's

(NYSE:CTO), – Closed investments of $330.8 million at a weighted average initial cash yield 9.3% in 2024 –– Raised $165.2 million of net proceeds under common ATM program in 2024 –– Current signed-not-open pipeline of $5.2 million – WINTER PARK, Fla., Feb. 20, 2025 (GLOBE NEWSWIRE) — CTO Realty Growth, Inc. (NYSE: CTO) (the “Company”

(NasdaqGM:TKNO), HOLLISTER, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) — Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2024,

(NASDAQ:YMAB), NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced it will report results for the fourth quarter and full year 2024 before

(NASDAQ:JAKK), SANTA MONICA, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) — JAKKS Pacific, Inc. (Nasdaq: JAKK) today reported financial results for the fourth quarter and fiscal year ended December 31, 2024. Fourth Quarter 2024 Net sales were $130.7 million, a year-over-year increase of 3% Toys/Consumer Products net sales were $118.2 million, a year-over-year decrease of 1%

(NASDAQ:CRDF), SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) — Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that it will hold a conference call on Thursday, February 27 after the close of trading to review financial results for the fourth

(NasdaqGM:NPCE), MOUNTAIN VIEW, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) — NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it has completed the previously announced plan to repurchase 5,270,845 shares of the Company's common stock from KCK Ltd. The repurchase of these shares allowed

(NASDAQ:HYFM), SHOEMAKERSVILLE, Pa., Feb. 20, 2025 (GLOBE NEWSWIRE) — Hydrofarm Holdings Group, Inc. (“Hydrofarm” or the “Company”) (Nasdaq: HYFM), a leading independent manufacturer and distributor of branded hydroponics equipment and supplies for controlled environment agriculture (“CEA”), today announced that it will host a conference call to review fourth quarter and full year 2024 results on